Castration

"Castration" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Surgical removal or artificial destruction of gonads.

Descriptor ID	D002369
MeSH Number(s)	E04.270.282 E04.950.165
Concept/Terms	Castration Castration Castrations Gonadectomy Gonadectomies

Below are MeSH descriptors whose meaning is more general than "Castration".

Analytical, Diagnostic and Therapeutic Techniques and Equipment [E]
Surgical Procedures, Operative [E04]
Endocrine Surgical Procedures [E04.270]
Castration [E04.270.282]
Urogenital Surgical Procedures [E04.950]
Castration [E04.950.165]

Below are MeSH descriptors whose meaning is related to "Castration".

Below are MeSH descriptors whose meaning is more specific than "Castration".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Castration" by people in this website by year, and whether "Castration" was a major or minor topic of these publications.

Bar chart showing 11 publications over 11 distinct years, with a maximum of 1 publications in 1996 and 2003 and 2004 and 2005 and 2007 and 2009 and 2010 and 2011 and 2012 and 2013 and 2019

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1996	0	1	1
2003	0	1	1
2004	1	0	1
2005	0	1	1
2007	1	0	1
2009	1	0	1
2010	0	1	1
2011	0	1	1
2012	1	0	1
2013	0	1	1
2019	0	1	1

Below are the most recent publications written about "Castration" by people in Profiles.

Shore N, Zurth C, Fricke R, Gieschen H, Graudenz K, Koskinen M, Ploeger B, Moss J, Prien O, Borghesi G, Petrenciuc O, Tammela TL, Kuss I, Verholen F, Smith MR, Fizazi K. Evaluation of Clinically Relevant Drug-Drug Interactions and Population Pharmacokinetics of Darolutamide in Patients with Nonmetastatic Castration-Resistant Prostate Cancer: Results of Pre-Specified and Post Hoc Analyses of the Phase III ARAMIS Trial. Target Oncol. 2019 10; 14(5):527-539.

View in: PubMed
Smith MR, Saad F, Oudard S, Shore N, Fizazi K, Sieber P, Tombal B, Damiao R, Marx G, Miller K, Van Veldhuizen P, Morote J, Ye Z, Dansey R, Goessl C. Denosumab and bone metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer: exploratory analyses by baseline prostate-specific antigen doubling time. J Clin Oncol. 2013 Oct 20; 31(30):3800-6.

View in: PubMed
Beach DF, Somer RA, Hoffman-Censits J, Lin J, Wong YN, Plimack E, Plimeck E, Hudes G, Vaughn D, Bernstein GT, Morris GJ. A wealth of new options: a case presentation of the management of castration-recurrent prostate cancer. Semin Oncol. 2012 Feb; 39(1):1-8.

View in: PubMed
Sheth SU, Palange D, Xu DZ, Wei D, Feketeova E, Lu Q, Reino DC, Qin X, Deitch EA. Testosterone depletion or blockade in male rats protects against trauma hemorrhagic shock-induced distant organ injury by limiting gut injury and subsequent production of biologically active mesenteric lymph. J Trauma. 2011 Dec; 71(6):1652-8.

View in: PubMed
Picus J, Halabi S, Kelly WK, Vogelzang NJ, Whang YE, Kaplan EB, Stadler WM, Small EJ. A phase 2 study of estramustine, docetaxel, and bevacizumab in men with castrate-resistant prostate cancer: results from Cancer and Leukemia Group B Study 90006. Cancer. 2011 Feb 01; 117(3):526-33.

View in: PubMed
Regan MM, O'Donnell EK, Kelly WK, Halabi S, Berry W, Urakami S, Kikuno N, Oh WK. Efficacy of carboplatin-taxane combinations in the management of castration-resistant prostate cancer: a pooled analysis of seven prospective clinical trials. Ann Oncol. 2010 Feb; 21(2):312-318.

View in: PubMed
Fizazi K, Le Maitre A, Hudes G, Berry WR, Kelly WK, Eymard JC, Logothetis CJ, Pignon JP, Michiels S. Addition of estramustine to chemotherapy and survival of patients with castration-refractory prostate cancer: a meta-analysis of individual patient data. Lancet Oncol. 2007 Nov; 8(11):994-1000.

View in: PubMed
Galsky MD, Small EJ, Oh WK, Chen I, Smith DC, Colevas AD, Martone L, Curley T, Delacruz A, Scher HI, Kelly WK. Multi-institutional randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer. J Clin Oncol. 2005 Mar 01; 23(7):1439-46.

View in: PubMed
Chevalier-Larsen ES, O'Brien CJ, Wang H, Jenkins SC, Holder L, Lieberman AP, Merry DE. Castration restores function and neurofilament alterations of aged symptomatic males in a transgenic mouse model of spinal and bulbar muscular atrophy. J Neurosci. 2004 May 19; 24(20):4778-86.

View in: PubMed
Smaletz O, Galsky M, Scher HI, DeLaCruz A, Slovin SF, Morris MJ, Solit DB, Davar U, Schwartz L, Kelly WK. Pilot study of epothilone B analog (BMS-247550) and estramustine phosphate in patients with progressive metastatic prostate cancer following castration. Ann Oncol. 2003 Oct; 14(10):1518-24.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement